Trial Profile
Open-label, Multicentre Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ceftaroline In Neonates And Young Infants With Late-onset Sepsis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Ceftaroline fosamil (Primary) ; Aminoglycosides; Ampicillin
- Indications Sepsis
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 20 Feb 2020 Results of Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis has been published in the Pediatric Infectious Disease Journal
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases